Medivation Slapped With Partial Hold Following PD-1 Confusion
This article was originally published in Scrip
Medivation's share price dipped slightly on news that the US FDA has put a partial clinical hold on the IND for the anticancer pidilizumab (MDV9300). The decision by the regulatory agency was made after Medivation disclosed that the mechanism of action of pidilizumab was not via PD-1 inhibition, and work was "underway" to determine exactly what the mechanism is.
Register for our free email digests: